Guest Host: Jen Golbeck

The chief executive of a pharmaceutical company caused a public outcry when he acquired sole U.S. rights to distribute a lifesaving drug and raised the price by more than 5000 percent. But the issue goes well beyond one company and one former hedge fund manager. A number of companies have been quietly cornering the market on older, off-patent drugs–and hiking prices. We speak with a medical historian about the economics of drug pricing, and why “generic” doesn’t guarantee competition.


  • Jeremy Greene MD; Professor of Medicine and the History of Medicine, Johns Hopkins University School of Medicine; Author, “Generic: The Unbranding of Modern Medicine.”

Related Links

Topics + Tags


comments powered by Disqus
Most Recent Shows

The Politics Hour — March 16, 2018

Friday, Mar 16 2018Maryland Senator Ben Cardin joins us to talk about the youth movement against gun violence, Russian sanctions, and more. D.C. Councilmember Mary Cheh shares her thoughts on relief for high water bills and news that D.C. Public Schools is taking over an all girls charter school.